KMT2C and acute myeloid leukemia: On the other hand, a recent report 27 and our own meta‐analysis of non‐epithelial cancers with the use of the GEPIA web server 28 indicated that, in comparison with respective healthy tissue, KMT2C is expressed at higher levels in glioblastoma multiforme (GBM), brain lower grade glioma (LGG), diffuse large B‐cell lymphomas (DLBL), acute myeloid leukemia (AML), and sarcomas (SARC; Appendix Fig S1).